Preterm Birth Prevention and Management Market Size

Preterm Birth Prevention and Management Market Outlook from 2024 to 2034

The global preterm birth prevention and management market size is estimated to stand at US$ 1.70 billion in 2024. As both developed and developing countries embrace therapeutics for preventing and managing preterm birth, the market is expected to exceed a valuation of US$ 4.49 billion by 2034, registering an impressive CAGR of 10.2%.

Preterm Birth Prevention and Management Market Overview:

Preterm birth prevention and management demand is on the rise since preterm birth has become a key healthcare problem. It is making a significant impact on both disability and perinatal death.
By 2034, there is likely to be a 2.65X surge in the adoption of preterm birth prevention and management. Healthcare professionals are implementing diverse strategies for preventing preterm birth
. This is propelling advancements in the market, with a foreseeable continuation of this trend.
The global trends in the preterm birth prevention and management industry spotlight a shift toward personalized and patient-centric care.

Attributes	Details
Preterm Birth Prevention and Management Market Size (2024)	US$ 1.70 billion
Preterm Birth Prevention and Management Market Forecasted Size (2034)	US$ 4.49 billion
Projected Value CAGR (2024 to 2034)	10.2%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Key Factors Influencing the Preterm Birth Prevention and Management Market Growth

Global Concerns Soar as Premature Births Skyrocket! One of the main concerns for governments and medical professionals globally nowadays is the startling rise in the frequency of premature births.

Government and nonprofit organizations have periodically implemented multiple measures to provide an adequate infrastructure for prenatal care. To decrease the number of recurring preterm birth cases, the National Consumer League (NCL) and patient advocacy organizations established the Preterm Birth Prevention Alliance (PBPA) in 2021.
The market is growing as a result of a rise in the use of preterm diagnostic tests for improved evaluation. Apart from the obvious risks that preterm birth poses to both the mother's and baby's lives, it also results in significant monetary consequences.

Maternal and Neonatal Health in the Spotlight! The increasing demand is rooted in the recognition of its profound impact on neonatal care in preterm births.

The World Health Organization (WHO) estimates that 15 million infants are born prematurely each year. This translates to about 11% global rate of premature births.
The rising awareness of the dangers and consequences associated with preterm labor management has led to an increased focus on proactive steps to prevent them.

Health Awareness Surge Fuels Market Boom! The market is also booming due to the expanding health awareness among individuals for preterm labor mitigation.

As information becomes more widely available, pregnant parents are becoming more knowledgeable of the possible dangers and difficulties related to preterm deliveries.
The shift in mindset contributes to the overall prevention and effective fatal health management. The Centers for Disease Control and Prevention report that after rising by 4% between 2020 and 2021, the preterm birth rate decreased by 1% in 2022 to 10.4%.

Targeted Therapies Take Center Stage in Preterm Birth Prevention! Increasing emphasis on targeted therapies also escalates the adoption rate of preterm birth prevention and management.

Advancements in medical research and technology allow for the development of targeted therapies that specifically address the factors contributing to preterm births.
Preterm births can be strongly prevented and managed with the use of precise medicines like tocolytics and corticosteroids, as well as surgical techniques like cervical cerclage and hydroxyprogesterone caproate.

Historical Preterm Birth Prevention and Management Market Statistic Analysis alongside Future Projections

From 2019 to 2023, the global preterm birth prevention and management industry showed promising growth, boasting a 9.0% CAGR. The application of progesterone and corticosteroid medications, among other therapeutic options, was prompted during this period by growing concerns over the mortality rate and long-term impairment associated with obstetric solutions for preterm delivery. These therapeutic methods are likely to continue to gain favor among individuals. The market for preterm birth prevention and management is anticipated to develop considerably as a result through 2034.

Historical CAGR (2019 to 2023)	9.0%
Forecasted CAGR (2024 to 2034)	10.2%

Prominent companies are actively investing in research to create innovative treatments. They are investigating novel combinations of therapies to successfully treat preterm delivery and associated consequences. By treating the fetus as the patient, University of Texas Medical Branch (UTMB) researchers unveiled a novel therapeutic approach in 2021 with the goal of lowering the prevalence of preterm births.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Preterm Birth Prevention and Management Market Trends

The evolving trends in the preterm birth prevention and management market indicate a promising shift toward more personalized and innovative approaches. Healthcare professionals and researchers are taking up a holistic perspective after recognizing the multifaceted nature of preterm birth. Modern diagnostics and customized treatment regimens together represent an important shift from the old one-size-fits-all approach.
Encouraging policies and programs from the government are fostering the development of solutions for managing and preventing preterm births.
There has been a noticeable increase in public and healthcare professional awareness initiatives aimed at educating people about the dangers of preterm birth and available early birth prevention strategies.

Preterm Birth Prevention and Management Market Analysis by Region

North America stands out as a dominant force in the preterm birth prevention and management industry. The region boasts a robust healthcare infrastructure, advanced medical research facilities, and a proactive approach towards maternal and infant health. There is likely to be significant growth in Asia Pacific. The increasing awareness of maternal and child healthcare, coupled with advancements in medical technology, creates a promising situation for growth of preterm birth prevention and management.

Country	Forecasted CAGR (2024 to 2034)
United States	8.1%
India	12.8%
China	11.5%
Japan	12.1%
Indonesia	13.0%

Government Initiatives Fuel Preterm Birth Prevention Market in the United States

Demand for preterm birth prevention and management in the United States is set to rise with an anticipated CAGR of 8.1% through 2034. Key factors influencing the demand include:

The government has occasionally implemented a number of programs to create an adequate infrastructure for prenatal care. Leading market players now have a ton of room because of this. The United States Department of Health and Human Services (HHS) provided almost US$ 350 million in grants to states nationwide in September 2021 to promote safe pregnancies and healthy infants. This simultaneously fuels the United States of America digital pregnancy test kits market.
In addition to the government, non-profit groups are concentrating on addressing the issue of premature births, which is propelling market expansion. The Office of Women's Health at Wayne State University, which acts as the SOS MATERNITY Network's coordination hub in Michigan, initiated a preterm birth awareness campaign in November 2023.

India's Preterm Birth Management Market Soars as Programs Multiply

The India preterm birth prevention and management market is forecasted to inflate at a CAGR of 12.8% through 2034. The primary factors bolstering the market expansion are:

In India, there is a growing demand for preterm birth prevention and treatment therapies due to the country's high infant death rate and rising preterm birth incidences. With over 3,519 100 instances, the country continues to be the top contributor to the global burden of preterm births, as reported by the WHO.
To address the growing number of premature babies, both public and private groups are launching multiple programs and campaigns. The government has started the India Newborn Action Plan, which is also known as Karyakram, Rashtriya Bal Suraksha. It establishes special newborn care units and improved labor rooms across the country.

Free Preconception Care Spurs Market Growth in China

Sales of preterm birth prevention and management drugs in China are estimated to record a CAGR of 11.5% through 2034. The main factors supporting this occurrence are:

Preterm birth rates have increased dramatically in China during the past few years. With around 1,172,300 cases, the country is now the second top contributor to the global preterm birth rate, according to the WHO. The preterm birth prevention and management market has gained attention as a result of the increase in preterm birth cases.
Supportive laws and rising government spending on building national infant care facilities are beneficial to market expansion, and this trend is likely to persist. In an effort to lower the frequency of birth abnormalities, the government has started providing free preconception care.

Free Clinic Admission Boosts Japan's Preterm Birth Prevention Market Growth

The preterm birth prevention and management market in Japan is likely to exhibit a CAGR of 12.1% through 2034. Reasons supporting this rapid adoption include:

Even with the strain of rising premature births, preterm birth rates in Japan decreased dramatically when obstetrical guidelines were implemented in 2008. But following 2021, it once more began to rise at an alarming pace.
Over the past three decades, Japan has tried intensive therapy for extremely preterm newborns born at fewer than twenty-five weeks gestation. Pregnant women in Japan are entitled to free clinic admission under the country's medical system.

Government Initiatives Propel Growth in Indonesia's Preterm Birth Management Market

The Indonesia preterm birth prevention and management market is expected to surge at a CAGR of 13.0% through 2034. Top factors supporting the market expansion include:

Preterm birth rates are high in Indonesia, with around 600,000 preterm births reported there each year. The Indonesian healthcare system is heavily burdened by it. As a result, demand for interventions to reduce premature birth risks is growing in Indonesia.
The MCH handbook for small babies and the national guideline for the management of LBW in primary health care, which were recently published by the Indonesian government, present potential for market participants in the area of LBW and premature birth interventions.

Preterm Birth Prevention and Management Market Analysis by Segment

As far as the therapy type is concerned, the progesterone segment is likely to dominate the industry in 2024, accounting for a 61.5% market share. Similarly, the parenteral segment is expected to take the lead when considering the route of administration, commanding a 78.8% preterm birth prevention and management market share in the same year. Likewise, when it comes to the distribution channel, the hospital pharmacies segment is anticipated to lead the way, holding an impressive 56.2% market share for the same year.

Segment	Market Share in 2024
Progesterone Therapy	61.5%
Parenteral	78.8%
Hospital Pharmacies	56.2%

Progesterone Therapy Leads in Preventing Preterm Birth

Progesterone therapy is the top choice for preventing preterm births. The following factors support this choice:

The demand for progesterone therapy is expected to grow rapidly, driven by the increasing adoption of this treatment for preterm birth prevention and management.
It is capable of providing quick results and it is also highly effective, all of which increase its attractiveness in the market.
Healthcare professionals highly recommend progesterone therapy because it doesn't involve surgery or anesthesia.
Progesterone is beneficial in preventing preterm births in cases of a short cervix, previous spontaneous preterm births, and various other pregnancy complications.

Healthcare Workers Prefer Parenteral Administration for Preterm Birth Management

The parenteral route dominates the global preterm birth prevention and management market.

Healthcare workers commonly use parenteral administration for therapeutics like progesterone and corticosteroids.
The parenteral route ensures better bioavailability and reliable dosing and avoids first-pass metabolism.
By bypassing the digestive system, the parenteral route minimizes variability in drug absorption, enhancing therapeutic effectiveness.
Advantages of parenteral administration contribute to its continued prevalence in healthcare practice.

Hospital Pharmacies Lead in Preterm Birth Prevention Medication Distribution

Hospital pharmacies hold the maximum revenue share in the distribution channel for preterm birth prevention and management.

Many patients choose government hospitals for cost-effectiveness, driving demand for preterm birth therapeutics at hospital pharmacies.
Hospital pharmacies, integrated into healthcare institutions, collaborate with various medical departments to provide a comprehensive approach to preterm birth prevention.
Shareholders are consistently investing in hospital pharmacies for the distribution of drugs related to preterm birth prevention and management.

Competitive Landscape

Top companies in the global preterm birth prevention and management market are strategically expanding their global footprint through initiatives like mergers, partnerships, product launches, approvals, collaborations, and acquisitions. These diverse approaches reflect their commitment to addressing preterm birth challenges while positioning themselves as industry leaders. Such dynamic strategies underscore their dedication to advancing healthcare solutions and fostering a broader impact on a global scale.

Recent Developments

The United States Food and Drug Administration authorized Opill®, Perrigo Company plc. announced in July 2023. This over-the-counter (OTC) oral contraceptive is exclusively available for use by adults and is progestin-only. The first birth control pill to be sold over-the-counter in the US was called Opill®.
The United States Food and Drug Administration authorized the Abrysvo (Respiratory Syncytial Virus Vaccine) in August 2023. This is the first vaccination licensed for expectant mothers to prevent severe lower respiratory tract illness (LRTD) and LRTD in babies under six months of age that is caused by the respiratory syncytial virus (RSV).

Key Preterm Birth Prevention and Management Market Players

Aquatic Remedies Pvt. Ltd.
Teva Pharmaceuticals USA, Inc.
Anglo French Drugs & Industries Limited
Biophar Lifesciences Pvt. Ltd.
Jasco Labs (P) Ltd.
BSA Pharma Inc.
Pfizer Inc.
Novartis AG
Sanofi S.A
AMAG Pharmaceuticals
Mylan

Key Segments in the Preterm Birth Prevention and Management Market Report

By Therapy Type:

Progesterone Therapy
Corticosteroid Therapy
Tocolytics Therapy
Antihypertensive Therapy
Magnesium Sulfate Therapy
Heparin Prophylaxis Therapy
Low-Dose Aspirin Therapy
Antibiotics Therapy

By Route of Administration:

Oral
Parenteral
Vaginal

By Patient Type:

Prior Spontaneous PTB
Preeclampsia
Short Cervix
Chronic Hypertension
Insulin-dependent
Twins
Antiphospholipid Antibody Syndrome
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Mail Order Pharmacies

By Region:

North America
Europe
Latin America
South Asia
East Asia
Oceania
Middle East and Africa

Frequently Asked Questions

How Big is the Preterm Birth Prevention and Management Market?

The preterm birth prevention and management industry is forecasted to be valued at US$ 1.70 billion in 2024.

What is the Demand Forecast of the Preterm Birth Prevention and Management?

The preterm birth prevention and management market Value is projected to surpass US$ 4.49 billion by 2034.

What is the Projected CAGR for the Preterm Birth Prevention and Management Market?

The CAGR of the preterm birth prevention and management industry is estimated to be around 10.2% through 2034.

Which Countries Drive the Demand for Preterm Birth Prevention and Management?

The United States, India, and Indonesia are key consumers of Preterm Birth Prevention and Management.

What is the Prevalence of Preterm Birth in India?

In India, the escalating issue of preterm birth is becoming a significant concern, and there is a projected 12.8% CAGR in the efforts toward its prevention and management.

What are the Global Trends of Preterm Birth?

Global trends in preterm birth show a concerning rise, with inadequate healthcare access and lifestyle changes contributing to an increase in premature deliveries

Table of Content

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapy Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2024 to 2034
5.3.1. Progesterone Therapy
5.3.2. Corticosteroid Therapy
5.3.3. Tocolytics Therapy
5.3.4. Antihypertensive Therapy
5.3.5. Magnesium Sulfate Therapy
5.3.6. Heparin Prophylaxis Therapy
5.3.7. Low-Dose Aspirin Therapy
5.3.8. Antibiotics Therapy
5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Therapy Type, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2024 to 2034
6.3.1. Oral
6.3.2. Parenteral
6.3.3. Vaginal
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Patient Type
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Patient Type , 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Patient Type , 2024 to 2034
7.3.1. Prior Spontaneous PTB
7.3.2. Preeclampsia
7.3.3. Short Cervix
7.3.4. Chronic Hypertension
7.3.5. Insulin-dependent
7.3.6. Twins
7.3.7. Antiphospholipid Antibody Syndrome
7.3.8. Others
7.4. Y-o-Y Growth Trend Analysis By Patient Type , 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Patient Type , 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2019 to 2023
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2024 to 2034
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Drug Stores
8.3.4. Mail Order Pharmacies
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. South Asia and Pacific
9.3.6. East Asia
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. U.S.
10.2.1.2. Canada
10.2.2. By Therapy Type
10.2.3. By Route of Administration
10.2.4. By Patient Type
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Therapy Type
10.3.3. By Route of Administration
10.3.4. By Patient Type
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Therapy Type
11.2.3. By Route of Administration
11.2.4. By Patient Type
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Therapy Type
11.3.3. By Route of Administration
11.3.4. By Patient Type
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. U.K.
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Western Europe
12.2.2. By Therapy Type
12.2.3. By Route of Administration
12.2.4. By Patient Type
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Therapy Type
12.3.3. By Route of Administration
12.3.4. By Patient Type
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Czech Republic
13.2.1.4. Romania
13.2.1.5. Rest of Eastern Europe
13.2.2. By Therapy Type
13.2.3. By Route of Administration
13.2.4. By Patient Type
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Therapy Type
13.3.3. By Route of Administration
13.3.4. By Patient Type
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Bangladesh
14.2.1.3. Australia
14.2.1.4. New Zealand
14.2.1.5. Rest of South Asia and Pacific
14.2.2. By Therapy Type
14.2.3. By Route of Administration
14.2.4. By Patient Type
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Therapy Type
14.3.3. By Route of Administration
14.3.4. By Patient Type
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Therapy Type
15.2.3. By Route of Administration
15.2.4. By Patient Type
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Therapy Type
15.3.3. By Route of Administration
15.3.4. By Patient Type
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Therapy Type
16.2.3. By Route of Administration
16.2.4. By Patient Type
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Therapy Type
16.3.3. By Route of Administration
16.3.4. By Patient Type
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. U.S.
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2023
17.1.2.1. By Therapy Type
17.1.2.2. By Route of Administration
17.1.2.3. By Patient Type
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2023
17.2.2.1. By Therapy Type
17.2.2.2. By Route of Administration
17.2.2.3. By Patient Type
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2023
17.3.2.1. By Therapy Type
17.3.2.2. By Route of Administration
17.3.2.3. By Patient Type
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2023
17.4.2.1. By Therapy Type
17.4.2.2. By Route of Administration
17.4.2.3. By Patient Type
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2023
17.5.2.1. By Therapy Type
17.5.2.2. By Route of Administration
17.5.2.3. By Patient Type
17.5.2.4. By Distribution Channel
17.6. U.K.
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2023
17.6.2.1. By Therapy Type
17.6.2.2. By Route of Administration
17.6.2.3. By Patient Type
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2023
17.7.2.1. By Therapy Type
17.7.2.2. By Route of Administration
17.7.2.3. By Patient Type
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2023
17.8.2.1. By Therapy Type
17.8.2.2. By Route of Administration
17.8.2.3. By Patient Type
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2023
17.9.2.1. By Therapy Type
17.9.2.2. By Route of Administration
17.9.2.3. By Patient Type
17.9.2.4. By Distribution Channel
17.10. Poland
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2023
17.10.2.1. By Therapy Type
17.10.2.2. By Route of Administration
17.10.2.3. By Patient Type
17.10.2.4. By Distribution Channel
17.11. Russia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2023
17.11.2.1. By Therapy Type
17.11.2.2. By Route of Administration
17.11.2.3. By Patient Type
17.11.2.4. By Distribution Channel
17.12. Czech Republic
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2023
17.12.2.1. By Therapy Type
17.12.2.2. By Route of Administration
17.12.2.3. By Patient Type
17.12.2.4. By Distribution Channel
17.13. Romania
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2023
17.13.2.1. By Therapy Type
17.13.2.2. By Route of Administration
17.13.2.3. By Patient Type
17.13.2.4. By Distribution Channel
17.14. India
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2023
17.14.2.1. By Therapy Type
17.14.2.2. By Route of Administration
17.14.2.3. By Patient Type
17.14.2.4. By Distribution Channel
17.15. Bangladesh
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2023
17.15.2.1. By Therapy Type
17.15.2.2. By Route of Administration
17.15.2.3. By Patient Type
17.15.2.4. By Distribution Channel
17.16. Australia
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2023
17.16.2.1. By Therapy Type
17.16.2.2. By Route of Administration
17.16.2.3. By Patient Type
17.16.2.4. By Distribution Channel
17.17. New Zealand
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2023
17.17.2.1. By Therapy Type
17.17.2.2. By Route of Administration
17.17.2.3. By Patient Type
17.17.2.4. By Distribution Channel
17.18. China
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2023
17.18.2.1. By Therapy Type
17.18.2.2. By Route of Administration
17.18.2.3. By Patient Type
17.18.2.4. By Distribution Channel
17.19. Japan
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2023
17.19.2.1. By Therapy Type
17.19.2.2. By Route of Administration
17.19.2.3. By Patient Type
17.19.2.4. By Distribution Channel
17.20. South Korea
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2023
17.20.2.1. By Therapy Type
17.20.2.2. By Route of Administration
17.20.2.3. By Patient Type
17.20.2.4. By Distribution Channel
17.21. GCC Countries
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2023
17.21.2.1. By Therapy Type
17.21.2.2. By Route of Administration
17.21.2.3. By Patient Type
17.21.2.4. By Distribution Channel
17.22. South Africa
17.22.1. Pricing Analysis
17.22.2. Market Share Analysis, 2023
17.22.2.1. By Therapy Type
17.22.2.2. By Route of Administration
17.22.2.3. By Patient Type
17.22.2.4. By Distribution Channel
17.23. Israel
17.23.1. Pricing Analysis
17.23.2. Market Share Analysis, 2023
17.23.2.1. By Therapy Type
17.23.2.2. By Route of Administration
17.23.2.3. By Patient Type
17.23.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Therapy Type
18.3.3. By Route of Administration
18.3.4. By Patient Type
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Aquatic Remedies Pvt. Ltd.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Teva Pharmaceuticals USA, Inc.
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Anglo French Drugs & Industries Limited
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Biophar Lifesciences Pvt. Ltd.
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Jasco Labs (P) Ltd.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. BSA Pharma Inc.
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Pfizer Inc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Novartis AG
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Sanofi S.A
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. AMAG Pharmaceuticals
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Mylan
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology

Preterm Birth Prevention and Management Market

Preterm Birth Prevention and Management Market Forecast by Progesterone and Corticosteroid Therapy 2024 to 2034